Effect of different doses of apatinib mesylate combined with chemotherapy on advanced oral cancer

CONCLUSION: Apatinib mesylate (250 mg) combined with chemotherapy can reach optimal efficacy with highest safety but least adverse effects for patients with advanced oral cancer.PMID:35035731 | PMC:PMC8748138
Source: American Journal of Translational Research - Category: Research Authors: Source Type: research